You might also like
AtriCure, Inc. is a global medical device company specializing in the development, manufacture, and sale of innovative solutions for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company provides advanced surgical and minimally invasive devices designed to improve patient outcomes in cardiothoracic and thoracic surgeries. AtriCure's products are distributed through a direct sales force in key markets and via distributors in other regions.
- Appendage Management - Offers products like the AtriClip® system to exclude the left atrial appendage, reducing stroke risk in patients with atrial fibrillation.
- Open Ablation - Provides devices used in open-heart procedures for cardiac tissue ablation, often during surgeries like mitral valve repair or coronary artery bypass.
- Pain Management - Features the cryoSPHERE® probe, which delivers temporary pain relief by freezing peripheral nerves during cardiothoracic or thoracic surgeries.
- Minimally Invasive Ablation - Supplies devices for standalone minimally invasive procedures, frequently used in hybrid approaches combining surgical and catheter ablation.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Michael H. Carrel ExecutiveBoard | President, CEO, and Director | Board Chair of Axonics, Inc.; Chair of Big Brothers Big Sisters of America; Board Member of MDMA | CEO since 2012; led revenue growth from $82M in 2013 to $399M in 2023; oversaw acquisitions of Estech, nContact, and SentreHEART. | View Report → |
Angela L. Wirick Executive | Chief Financial Officer (CFO) | Business Advisory Council Member at the University of Dayton | Joined in 2014; became CFO in 2020; oversees Finance and IT functions; CPA with a background in public accounting. | |
Deborah Yount Executive | Chief Human Resources Officer (CHRO) | None | Joined in 2022; over 30 years of HR leadership experience; previously held roles at Medtronic and Texas Instruments. | |
Douglas J. Seith Executive | Chief Operating Officer (COO) | None | Joined in 2004; COO since 2015; over 30 years of experience in cardiothoracic and general surgery sales and marketing. | |
Justin J. Noznesky Executive | Chief Marketing and Strategy Officer | None | Joined in 2014; leads marketing and strategy; over 20 years of experience in strategic planning, M&A, and global marketing. | |
Karl S. Dahlquist Executive | Chief Legal Officer | None | Joined in 2013; oversees legal, regulatory, and compliance functions; licensed attorney and Certified Compliance & Ethics Professional (CCEP). | |
Salvatore Privitera Executive | Chief Technical Officer | Advisory Board Member at University of Buffalo; Board Member of Cincinnati AHA and Ohio Life Sciences | Joined in 2008; CTO since 2017; named inventor on over 50 U.S. patents; extensive R&D experience. | |
Vinayak Doraiswamy Executive | Chief Scientific Officer | None | Joined in 2017; oversees clinical, regulatory, and scientific affairs; extensive experience in clinical trials and Afib market. | |
B. Kristine Johnson Board | Board Chair | Director at ClearPoint Neuro, Inc. and Paragon28, Inc.; University of Minnesota Foundation Investment Advisors | Board Chair since 2017; extensive experience in healthcare and venture capital; previously led Affinity Capital Management. | |
Deborah H. Telman Board | Director | EVP, Corporate Affairs and General Counsel at Gilead Sciences, Inc. | Director since 2021; extensive legal and corporate affairs experience; previously EVP and General Counsel at Organon & Co.. | |
Karen N. Prange Board | Director | Industrial Advisor at EQT Group; Board Member at Nevro Corp., Embecta Corp., and WSAudiology; Strategic Advisor at Nuvo Group Ltd. | Director since 2019; led a $6B business at Henry Schein; extensive experience in healthcare and medical devices. | |
Maggie Yuen Board | Director | CFO at Penumbra, Inc. | Director since 2021; over 20 years of financial and operational leadership in manufacturing and medical devices. | |
Regina E. Groves Board | Director | Board Member at Fulgent Genetics, Inc. and Advanced NanoTherapies, Inc. | Director since 2017; expertise in enterprise risk, strategy, and finance; qualifies as an SEC "audit committee financial expert". | |
Robert S. White Board | Director (Incoming Board Chair) | Operating Partner at EW Healthcare Partners; Board Member at BioTissue, Vital Connect, and Cardiac Dimensions | Director since 2013; incoming Board Chair; extensive leadership in medical devices and venture capital. | |
Shlomo Nachman Board | Director | Board Member at private medical device companies; Board Member of Arnold and Mable Beckman Foundation | Director since 2024; extensive leadership in medical devices, including at Johnson & Johnson. | |
Sven A. Wehrwein Board | Director | Board Member at Proto Labs, Inc. and SPS Commerce, Inc. | Director since 2016; Chair of Audit Committee; extensive financial and governance expertise; recognized as an SEC "audit committee financial expert". |
- With the expected declines in your U.S. minimally invasive ablation and MIS appendage management franchises due to PFA adoption, what specific strategies are you implementing to mitigate this pressure and sustain growth in these segments?
- Given that international revenue growth is outpacing the U.S. but comes with lower gross margins, how do you plan to offset the impact on overall profitability while continuing to expand globally?
- You mentioned that the majority of your growth is volume-based despite new product launches that could offer pricing uplifts; can you elaborate on your pricing strategy and how it factors into your revenue and margin expectations for 2025?
- Considering your significant R&D investments in 2025, including up to $10 million in milestone payments for your PFA platform, how will these expenses impact your profitability targets, and when do you expect these investments to generate meaningful returns?
- As you explore expanding cryo nerve block therapy into new areas like lower extremity amputations, what challenges do you foresee in regulatory approval and market adoption, and how confident are you in the timeline for these new indications to contribute to revenue?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The primary competitor in the cardiac surgery market, providing surgical ablation products and left atrial appendage management (LAAM) devices used by physicians for the treatment of atrial fibrillation (Afib) and related conditions. |